Globe Newswire08.22.17
QIAGEN and Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, have announced they have implemented the PAXgene Blood ccfDNA Tube* sample collection in Clinical Genomics’ Colvera colorectal cancer recurrence assay. Colvera, an integrated liquid biopsy solution, is designed to enable easy and accurate monitoring for recurrence of colorectal cancer with a simple blood test collected in a physician’s office.
“The Colvera test represents a unique opportunity for convenient, non-invasive monitoring of colorectal cancer patients by detecting methylated circulating tumor DNA that may indicate recurrence of a cancer. We are pleased to collaborate with Clinical Genomics in expanding the range of benefits made possible through liquid biopsies, which hold great promise for improving the lives of patients in cancer and other fields of medicine,” said Thierry Bernard, senior vice president and head of QIAGEN’s Molecular Diagnostics Business Area.
“We are extremely pleased to use the highly automated QIAsymphony PAXgene Blood ccfDNA collection and sample processing workflow for collection and handling of Colvera samples. As a long-term commercial and research partner of QIAGEN, we have a great deal of confidence in this new solution," said Dr. Lawrence LaPointe, CEO of Clinical Genomics. “We are excited to roll out the PAXgene System as the front-end solution to allow physicians to provide Colvera testing to CRC patients as conveniently as possible. PAXgene allows a simple blood collection at the physician’s office, with no on-site processing required, which is a great step forward from our alternative sample collection methods.”
Clinical Genomics and QIAGEN have demonstrated that PAXgene ccfDNA yield and Colvera assay performance is equivalent to the performance from blood samples collected in EDTA tubes, spun down to plasma and frozen within eight hours of collection—whereby the PAXgene process demonstrated a significantly superior ease of use and robustness. These findings will be presented in a poster at the Association for Molecular Pathology Annual Meeting to be held in November in Salt Lake City, Utah (Murray D et al, “Effect of blood collection tubes on circulating tumor DNA (ctDNA) yield and specificity”).
*The PAXgene Blood ccfDNA System was developed by PreAnalytiX GmbH, a QIAGEN/BD joint venture company
“The Colvera test represents a unique opportunity for convenient, non-invasive monitoring of colorectal cancer patients by detecting methylated circulating tumor DNA that may indicate recurrence of a cancer. We are pleased to collaborate with Clinical Genomics in expanding the range of benefits made possible through liquid biopsies, which hold great promise for improving the lives of patients in cancer and other fields of medicine,” said Thierry Bernard, senior vice president and head of QIAGEN’s Molecular Diagnostics Business Area.
“We are extremely pleased to use the highly automated QIAsymphony PAXgene Blood ccfDNA collection and sample processing workflow for collection and handling of Colvera samples. As a long-term commercial and research partner of QIAGEN, we have a great deal of confidence in this new solution," said Dr. Lawrence LaPointe, CEO of Clinical Genomics. “We are excited to roll out the PAXgene System as the front-end solution to allow physicians to provide Colvera testing to CRC patients as conveniently as possible. PAXgene allows a simple blood collection at the physician’s office, with no on-site processing required, which is a great step forward from our alternative sample collection methods.”
Clinical Genomics and QIAGEN have demonstrated that PAXgene ccfDNA yield and Colvera assay performance is equivalent to the performance from blood samples collected in EDTA tubes, spun down to plasma and frozen within eight hours of collection—whereby the PAXgene process demonstrated a significantly superior ease of use and robustness. These findings will be presented in a poster at the Association for Molecular Pathology Annual Meeting to be held in November in Salt Lake City, Utah (Murray D et al, “Effect of blood collection tubes on circulating tumor DNA (ctDNA) yield and specificity”).
*The PAXgene Blood ccfDNA System was developed by PreAnalytiX GmbH, a QIAGEN/BD joint venture company